Stockreport

EXCLUSIVE: Vivani Medical's Type 2 Diabetes Treatment NPM-119 Subdermal Implant's NDA Gains FDA Clearance For Clinical Use [Yahoo! Finance]

Vivani Medical, Inc.  (VANI) 
PDF This study will assess the safety, tolerability, and pharmacokinetics of Vivani's innovative six-month GLP-1 implant, designed to treat type 2 diabetes. LIBERATE-1 is [Read more]